Dose Insider / Glossary / TBWL

Total body weight loss (TBWL)The percentage every weight trial reports

Updated November 20, 2026 · 4 min read · Corcelles 2016; SURMOUNT-1; STEP 1; ATTAIN-1; Saxenda, Qsymia and Contrave labels

Total body weight loss, or TBWL, is the weight a person has lost as a percentage of their starting weight: the starting weight minus the current weight, divided by the starting weight, times 100. Someone who goes from 220 lb to 198 lb has lost 22 lb, which is 10% TBWL. It is the number GLP-1 trials report as their main result, written as the percentage change in body weight.1,2

20.9%GLP-1 medicines, Zepbound 15 mg, 72 weeks, average weight lost in trials
Average weight lost in trials% of starting weight, drug arm, top doseGLP-1 MEDICINESZepbound 15 mg, 72 weeks20.9%Wegovy 2.4 mg, 68 weeks14.9%Orforglipron, 72 weeks11.2%Saxenda 3 mg, 56 weeks7.4%FOR COMPARISONQsymia top dose, 1 year10.9%Contrave, 56 weeks5.4%Gastric bypass, 1 year30.0%Average weight lost intrials% of starting weight, drug arm, top doseGLP-1 MEDICINESZepbound 15 mg, 72 weeks20.9%Wegovy 2.4 mg, 68 weeks14.9%Orforglipron, 72 weeks11.2%Saxenda 3 mg, 56 weeks7.4%FOR COMPARISONQsymia top dose, 1 year10.9%Contrave, 56 weeks5.4%Gastric bypass, 1 year30.0%

Different trials and people; not a head-to-head ranking.

On this page

Why this measure won

There is no agreed way to describe weight loss after bariatric surgery, where an older measure, percent excess weight loss, is also used. A 2016 study of 2,420 people after gastric bypass compared the two. They started at an average BMI of 46.8. After one year they had lost on average 30.0% of total body weight, 68.5% of excess weight, and their BMI had fallen by 14.1 points on average. The excess-weight figure depended strongly on how heavy people were at the start, a correlation of −0.52 with starting BMI, while total weight loss did not, 0.04. The authors concluded that total weight loss should be the measure of choice. They counted under 20% at 12 months as a suboptimal result, which applied to 11.3% of patients.3

What the trials report

People started at similar weights: 104.8 kg on average in SURMOUNT-1, 106.2 kg in the Saxenda trial and about 115 to 119 kg in the Qsymia trials.2,5,6 Still, these are averages from different trials, with different lengths and people, so they are not a ranking.

The 5%, 10% and 15% marks

Trials also report the share of people who passed set levels of TBWL, usually 5%, 10% and 15% of starting weight. In STEP 1, 5% or more was reached by 86.4% on semaglutide against 31.5% on placebo, 10% or more by 69.1% against 12.0%, and 15% or more by 50.5% against 4.9%.1 The Saxenda label turns one of these marks into a rule. Weight is checked 16 weeks after starting, and Saxenda is stopped if the person has not lost at least 4% of their starting weight, since a meaningful loss is then unlikely with more treatment.5

The older medicines show the same pattern at lower levels. On Saxenda, in adults without diabetes, at least 5% was lost by 62.3% against 34.4% on placebo, and more than 10% by 33.9% against 15.4%.5 On Contrave in COR-I, at least 5% was lost by 42% against 17%, and at least 10% by 21% against 7%.7 On Qsymia, at least 10% was lost by 47% on the top dose, 19% on the lowest dose and 7% on placebo.6 These shares say more than the average does, because they show how many people reached each level.

Working out your own number

Because TBWL is a share of the starting weight, the starting weight has to be recorded on day one. The same 22 lb is 10% for someone who started at 220 lb and about 7% for someone who started at 300 lb, which is why the percentage, not the pounds, is what compares with trial results.

Sources

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. Funded by Novo Nordisk; NCT03548935. doi:10.1056/NEJMoa2032183
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. NCT04184622. doi:10.1056/NEJMoa2206038
  3. Corcelles R, Boules M, Froylich D, et al. Total weight loss as the outcome measure of choice after Roux-en-Y gastric bypass. Obes Surg 2016;26:1794-1798. doi:10.1007/s11695-015-2022-y
  4. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. Funded by Eli Lilly. doi:10.1056/NEJMoa2511774
  5. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published June 15, 2026; boxed warning, recent major changes and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
  6. QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, U.S. National Library of Medicine, version published April 24, 2026; sections 1, 2, 4, 5, 6.1, 8.1 and 14. dailymed.nlm.nih.gov
  7. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. DailyMed, U.S. National Library of Medicine, version published November 17, 2025; boxed warning and sections 1, 2, 4, 5, 6.1, 7.2 and 14. dailymed.nlm.nih.gov

Related analyses

Log your starting weight once, and the app shows your total weight loss as a percentage.

Open Dose Insider